New Cancer Vaccine Approach Directly Targets Dendritic Cells

“Celldex Therapeutics announced today that final data from its Phase 1 study of CDX-1401 in solid tumors, including long-term patient follow-up, have been published inScience Translational Medicine. The data demonstrate robust antibody and T cell responses and evidence of clinical benefit in patients with very advanced cancers and suggest that CDX-1401 may predispose patients to better outcomes on subsequent therapy with checkpoint inhibitors. CDX-1401 is an off-the-shelf vaccine consisting of a fully human monoclonal antibody with specificity for the dendritic cell receptor DEC-205 linked to the NY-ESO-1 tumor antigen. The vaccine is designed to activate the patient’s immune system against cancers that express the tumor marker NY-ESO-1. While the function of NY-ESO-1 continues to be explored, references in the literature suggest that its expression might reflect the acquisition of properties that cancers find useful, such as immortality, self-renewal, migratory ability and the capacity to invade.”

Editor’s note: Cancer vaccines like CDX-1401 are a type of immunotherapy, meaning that they boost a patient’s own immune system to fight cancer. CDX-1401 is able to attack tumor cells because the tumor cells have a molecule called NY-ESO-1 that CDX-1401 recognizes. We recently published a story about another treatment that is meant for patients whose tumors have NY-ESO-1. To learn more about how patients can use molecular testing to see if particular treatments might work for them, click here.


Thematic Session 10: Update on treatment options for patients with CRPC

“There are new treatment options for castration resistant prostate cancer (CRPC) but finding the optimal strategy and selecting the right patient is still fraught with challenges and difficulties, according to uro-oncology experts during a thematic session at the 29th Annual EAU Congress in Stockholm, Sweden.

“ ‘With many prostate cancer patients hoping for a better life without symptoms of the disease, the aim is to identify which new drugs, or a combination of these drugs, can offer prolong survival or effectively palliate bone disease,’ said Prof. Maria De Santis who chaired Thematic Session 10.

“The session focussed on castration-resistant prostate cancer (CRPC) which is often considered one of the toughest challenges in uro-oncology since despite repeated treatments the disease accelerates or progresses with severe impact on quality of life (QoL).”

Editor’s note: This article is about an event at a urology conference in Sweden. During the event, participants discussed the latest in prostate cancer treatment, with a focus on castration-resistant prostate cancer (CRPC).


Dendreon Says Prelim. Data from LT Phase II STAND Study Will Be Presented at EAU Congress, Will Show Immune Responses with PROVENGE Enhanced, Sustained

“Dendreon Corporation (NASDAQ: DNDN) today announced the presentation of preliminary data from a long-term analysis of the Phase II STAND study demonstrating that tumor-specific T-cell responses appear to be enhanced and sustained when PROVENGE^® (sipuleucel-T) is given after androgen deprivation therapy (ADT) in patients with biochemically-recurrent prostate cancer (BRPC) at high risk for metastases. These data will be presented at the 29^th Annual European Association of Urology (EAU) Congress taking place from April 11-15, 2014 in Stockholm, Sweden.”

Editor’s note: This story is about a study that demonstrated positive patient responses when the cancer vaccine Provenge was given as a prostate cancer treatment after patients were first treated with androgen deprivation therapy (ADT). The study focused on patients with biochemically-recurrent prostate cancer (BRPC) at high risk for metastasis.


Using a Person's Own Immune System to Fight Cancer: Phase I Clinical Trial of New Immunotherapy Beginning

“Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.”

Editor’s note: This treatment looks for and targets cells that have the protein NY-ESO-1. Only 10-15% of tumors have NY-ESO-1, and patients’ tumors must test positive for NY-ESO-1 in order for the patients to enroll in the trial. Learn more about immunotherapy and clinical trials here.


Using a Person's Own Immune System to Fight Cancer: Phase I Clinical Trial of New Immunotherapy Beginning

“Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.”

Editor’s note: This treatment looks for and targets cells that have the protein NY-ESO-1. Only 10-15% of tumors have NY-ESO-1, and patients’ tumors must test positive for NY-ESO-1 in order for the patients to enroll in the trial. Learn more about immunotherapy and clinical trials here.


Using a Person's Own Immune System to Fight Cancer: Phase I Clinical Trial of New Immunotherapy Beginning

“Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.”

Editor’s note: This treatment looks for and targets cells that have the protein NY-ESO-1. Only 10-15% of tumors have NY-ESO-1, and patients’ tumors must test positive for NY-ESO-1 in order for the patients to enroll in the trial. Learn more about immunotherapy and clinical trials here.


Deploying the Body's Army

“More than a century ago, American bone surgeon William Coley came across the case of Fred Stein, whose aggressive cheek sarcoma had disappeared after he suffered a Streptococcus pyogenesinfection following surgery to remove part of the large tumor. Seven years later, Coley tracked Stein down and found him alive, with no evidence of cancer. Amazed, Coley speculated that the immune response to the bacterial infection had played an integral role in fighting the disease, and the doctor went on to inoculate more than 10 other patients suffering from inoperable tumors with Streptococcus bacteria. Sure enough, several of those who survived the infection—and one who did not—experienced tumor reduction.”

Editor’s note: This article is a great overview of immunotherapy for treating cancer. Immunotherapy drugs boost a patient’s own immune system to fight cancer. Learn more.


Deploying the Body's Army

“More than a century ago, American bone surgeon William Coley came across the case of Fred Stein, whose aggressive cheek sarcoma had disappeared after he suffered a Streptococcus pyogenesinfection following surgery to remove part of the large tumor. Seven years later, Coley tracked Stein down and found him alive, with no evidence of cancer. Amazed, Coley speculated that the immune response to the bacterial infection had played an integral role in fighting the disease, and the doctor went on to inoculate more than 10 other patients suffering from inoperable tumors with Streptococcus bacteria. Sure enough, several of those who survived the infection—and one who did not—experienced tumor reduction.”

Editor’s note: This article is a great overview of immunotherapy for treating cancer. Immunotherapy drugs boost a patient’s own immune system to fight cancer. Learn more.


Deploying the Body's Army

“More than a century ago, American bone surgeon William Coley came across the case of Fred Stein, whose aggressive cheek sarcoma had disappeared after he suffered a Streptococcus pyogenesinfection following surgery to remove part of the large tumor. Seven years later, Coley tracked Stein down and found him alive, with no evidence of cancer. Amazed, Coley speculated that the immune response to the bacterial infection had played an integral role in fighting the disease, and the doctor went on to inoculate more than 10 other patients suffering from inoperable tumors with Streptococcus bacteria. Sure enough, several of those who survived the infection—and one who did not—experienced tumor reduction.”

Editor’s note: This article is a great overview of immunotherapy for treating cancer. Immunotherapy drugs boost a patient’s own immune system to fight cancer. Learn more.